Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has commenced a long-term (six month) study of Oral-lyn, the Company’s proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus.
